<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="299">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01425320</url>
  </required_header>
  <id_info>
    <org_study_id>225678-003</org_study_id>
    <nct_id>NCT01425320</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Dapsone-Adapalene Fixed Combination Gel in Acne</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate the pharmacokinetics, safety and tolerability of dapsone and
      adapalene following topical administration of 2 formulations of dapsone/adapalene fixed
      combination gel, dapsone 5% gel (ACZONE®), and adapalene 0.3% gel (Differin®) in subjects
      with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was never initiated due to company decision. No study subjects were ever enrolled or
    dosed.
  </why_stopped>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor)</study_design>
  <primary_outcome>
    <measure>Plasma Levels of Dapsone</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Levels of Dapsone</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Levels of Adapalene</measure>
    <time_frame>Day 1</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Levels of Adapalene</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Local Dermal Tolerability Rating Using a 4-Point Scale</measure>
    <time_frame>Day 14</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Fixed Combination dapsone/adapalene Formulation A Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fixed Combination dapsone/adapalene Formulation B Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dapsone 5% gel (ACZONE®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adapalene 0.3% gel (Differin®)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed Combination dapsone/adapalene Formulation A Gel</intervention_name>
    <description>Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
    <arm_group_label>Fixed Combination dapsone/adapalene Formulation A Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fixed Combination dapsone/adapalene Formulation B Gel</intervention_name>
    <description>Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
    <arm_group_label>Fixed Combination dapsone/adapalene Formulation B Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dapsone 5% gel</intervention_name>
    <description>Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
    <arm_group_label>dapsone 5% gel (ACZONE®)</arm_group_label>
    <other_name>ACZONE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adapalene 0.3% gel</intervention_name>
    <description>Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.</description>
    <arm_group_label>adapalene 0.3% gel (Differin®)</arm_group_label>
    <other_name>Differin®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate acne on the face

          -  Willing to avoid swimming during the study

          -  Willing to avoid excessive sunlight and ultraviolet light (e.g., tanning beds)during
             the study

          -  Willing to avoid moisturizers, sunscreens, cosmetics, and chemical peels during the
             study

        Exclusion Criteria:

          -  Severe cystic acne

          -  Use of topical or oral retinoids within 4 weeks

          -  Use of isotretinoin within 3 months

          -  Use of dapsone or adapalene within 3 months

          -  Anticipated need to engage in activities/exercise that would cause profuse sweating

          -  Donated blood or equivalent blood loss within 90 days
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Allergan</affiliation>
  </overall_official>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <lastchanged_date>November 16, 2012</lastchanged_date>
  <firstreceived_date>August 26, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Dapsone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
